Przygodzki Tomasz, Talar Marcin, Blazejczyk Agnieszka, Kalchenko Vyacheslav, Watala Cezary
Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Lodz, Poland.
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
PLoS One. 2016 Jan 11;11(1):e0146346. doi: 10.1371/journal.pone.0146346. eCollection 2016.
The paper describes an alternative method for quantification of in vivo ADP-induced thromboembolism. The aim of the studies was to develop a method of quantification which would not require either extravasation or labelling of platelets. Our proposed approach is based on the monitoring of changes of blood flow with the use of laser Doppler flowmetry.
Mice of C57Bl strain were used in the study. ADP was injected to the vena cava and blood flow was monitored with the use of a laser Doppler flowmeter in the mesentery. Measurements in platelet-depleted mice, mice pretreated with cangrelor, an ADP receptor antagonist, and eptifibatide, a blocker of fibrinogen binding to GPIIbIIIa, were conducted as the proof-of-concept in the performed experiments. Intravital microscopy and ex vivo imaging of organs was performed to identify the sites of aggregate formation resulting from ADP injection.
The injection of ADP resulted in a dose-dependent reduction of the blood flow in the mesentery. These responses were fully attributable to blood platelet aggregation, as shown by the lack of the effect in platelet-depleted mice, and significantly reduced responses in mice pretreated with cangrelor and eptifibatide. No platelet aggregate formation in mesenteric vessels was revealed by intravital microscopy, while ex vivo imaging showed accumulation of fluorescent labelled platelets in the lung.
Injection of ADP to the venous system results in the formation of platelet aggregates predominantly in the lung. This results in reversible blood flow cessation in peripheral blood vessels. The measurement of this blood flow cessation in the mesentery allows indirect measurement of ADP-induced pulmonary thromboembolism. We suggest that this approach can be useful for in vivo screening for antiplatelet drug candidates.
本文描述了一种用于定量体内ADP诱导的血栓栓塞的替代方法。这些研究的目的是开发一种无需血小板外渗或标记的定量方法。我们提出的方法基于使用激光多普勒血流仪监测血流变化。
研究中使用了C57Bl品系的小鼠。将ADP注入腔静脉,并使用激光多普勒血流仪在肠系膜中监测血流。在血小板减少的小鼠、用坎格雷洛(一种ADP受体拮抗剂)和依替巴肽(一种纤维蛋白原与GPIIbIIIa结合的阻滞剂)预处理的小鼠中进行测量,作为所进行实验的概念验证。进行了活体显微镜检查和器官的离体成像,以确定ADP注射导致的聚集形成部位。
注射ADP导致肠系膜血流呈剂量依赖性减少。如血小板减少的小鼠中无此效应所示,这些反应完全归因于血小板聚集,并且在用坎格雷洛和依替巴肽预处理的小鼠中反应显著降低。活体显微镜检查未发现肠系膜血管中有血小板聚集形成,而离体成像显示荧光标记的血小板在肺中积聚。
向静脉系统注射ADP主要导致肺中形成血小板聚集体。这导致外周血管中血流可逆性停止。测量肠系膜中这种血流停止情况可间接测量ADP诱导的肺血栓栓塞。我们认为这种方法可用于体内筛选抗血小板候选药物。